Trends in Utilization and Expenditure for Onychomycosis Treatments in the United States in 2013–2016
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-019-00425-x
Abstract: To the Editor, Onychomycosis is common in the US, affecting > 12% of the population [1]. Efinaconazole (Jublia®) and tavaborole (Kerydin®) are topical antifungal treatments that were approved by the US FDA in 2014 for… read more here.
Keywords: 2013 2016; ciclopirox; terbinafine; expenditure ... See more keywords